MGTA Annual CFF
$2.88 M
-$86.72 M-96.79%
31 December 2022
Summary:
As of January 21, 2025, MGTA annual cash flow from financing activities is $2.88 million, with the most recent change of -$86.72 million (-96.79%) on December 31, 2022. During the last 3 years, it has fallen by -$59.42 million (-95.38%).MGTA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MGTA Quarterly CFF
$0.00
$0.000.00%
30 June 2023
Summary:
As of January 21, 2025, MGTA quarterly cash flow from financing activities is $0.00, unchanged on June 30, 2023. Over the past year, it has dropped by -$49.00 thousand (-100.00%).MGTA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MGTA TTM CFF
$2.83 M
-$49.00 K-1.70%
30 June 2023
Summary:
As of January 21, 2025, MGTA TTM cash flow from financing activities is $2.83 million, with the most recent change of -$49.00 thousand (-1.70%) on June 30, 2023. Over the past year, it has increased by +$2.45 million (+652.39%).MGTA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MGTA Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -96.8% | -100.0% | +652.4% |
| 3 y3 years | -95.4% | -100.0% | -95.8% |
| 5 y5 years | -96.0% | -100.0% | -95.5% |
MGTA Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -98.0% | -100.0% | -98.1% |
Magenta Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | $0.00(0.0%) | $2.83 M(-1.7%) |
| Mar 2023 | - | $0.00(-100.0%) | $2.88 M(0.0%) |
| Dec 2022 | $2.88 M(-96.8%) | $66.00 K(-97.6%) | $2.88 M(-2.0%) |
| Sept 2022 | - | $2.76 M(+5538.8%) | $2.94 M(+680.9%) |
| June 2022 | - | $49.00 K(>+9900.0%) | $376.00 K(-99.6%) |
| Mar 2022 | - | $0.00(-100.0%) | $89.18 M(-0.5%) |
| Dec 2021 | $89.60 M(+32.3%) | $124.00 K(-38.9%) | $89.60 M(-1.2%) |
| Sept 2021 | - | $203.00 K(-99.8%) | $90.66 M(+0.4%) |
| June 2021 | - | $88.86 M(>+9900.0%) | $90.29 M(+34.7%) |
| Mar 2021 | - | $418.00 K(-64.5%) | $67.03 M(-1.0%) |
| Dec 2020 | $67.74 M | $1.18 M(-841.5%) | $67.74 M(+0.4%) |
| Sept 2020 | - | -$159.00 K(-100.2%) | $67.47 M(-0.4%) |
| June 2020 | - | $65.59 M(+5735.9%) | $67.73 M(+7.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | $1.12 M(+23.0%) | $62.86 M(+0.9%) |
| Dec 2019 | $62.30 M(-56.2%) | $914.00 K(+862.1%) | $62.30 M(+2.3%) |
| Sept 2019 | - | $95.00 K(-99.8%) | $60.91 M(+1.4%) |
| June 2019 | - | $60.73 M(>+9900.0%) | $60.08 M(-58.0%) |
| Mar 2019 | - | $563.00 K(-218.3%) | $142.88 M(+0.5%) |
| Dec 2018 | $142.15 M(+98.8%) | -$476.00 K(-34.9%) | $142.15 M(-0.3%) |
| Sept 2018 | - | -$731.00 K(-100.5%) | $142.62 M(-1.9%) |
| June 2018 | - | $143.53 M(<-9900.0%) | $145.35 M(+123.3%) |
| Mar 2018 | - | -$175.00 K(<-9900.0%) | $65.10 M(-8.9%) |
| Dec 2017 | $71.49 M(+567.4%) | $0.00(-100.0%) | $71.49 M(0.0%) |
| Sept 2017 | - | $2.00 M(-96.8%) | $71.49 M(+2.9%) |
| June 2017 | - | $63.27 M(+918.2%) | $69.49 M(+1018.2%) |
| Mar 2017 | - | $6.21 M | $6.21 M |
| Dec 2016 | $10.71 M | - | - |
FAQ
- What is Magenta Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Magenta Therapeutics?
- What is Magenta Therapeutics annual CFF year-on-year change?
- What is Magenta Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Magenta Therapeutics?
- What is Magenta Therapeutics quarterly CFF year-on-year change?
- What is Magenta Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Magenta Therapeutics?
- What is Magenta Therapeutics TTM CFF year-on-year change?
What is Magenta Therapeutics annual cash flow from financing activities?
The current annual CFF of MGTA is $2.88 M
What is the all time high annual CFF for Magenta Therapeutics?
Magenta Therapeutics all-time high annual cash flow from financing activities is $142.15 M
What is Magenta Therapeutics annual CFF year-on-year change?
Over the past year, MGTA annual cash flow from financing activities has changed by -$86.72 M (-96.79%)
What is Magenta Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of MGTA is $0.00
What is the all time high quarterly CFF for Magenta Therapeutics?
Magenta Therapeutics all-time high quarterly cash flow from financing activities is $143.53 M
What is Magenta Therapeutics quarterly CFF year-on-year change?
Over the past year, MGTA quarterly cash flow from financing activities has changed by -$49.00 K (-100.00%)
What is Magenta Therapeutics TTM cash flow from financing activities?
The current TTM CFF of MGTA is $2.83 M
What is the all time high TTM CFF for Magenta Therapeutics?
Magenta Therapeutics all-time high TTM cash flow from financing activities is $145.35 M
What is Magenta Therapeutics TTM CFF year-on-year change?
Over the past year, MGTA TTM cash flow from financing activities has changed by +$2.45 M (+652.39%)